Pharma dockets range from NCE scaffolds and prodrugs to complex combinations—each with distinct examiner mixes and claim strategies. Ranking by allowance rate within A61K/C07D/C07H (and C12N when drug-product claims apply) isolates performance in the chemistry you actually prosecute. It levels the field across firm size and mix and centers the outcome clients care about: Did the work convert to granted rights in this industry? CPC granularity keeps comparisons apples-to-apples, so an NCE specialist isn’t measured against biologics-heavy work, and vice versa.
The result: fair, comparable standings you can defend in a partner meeting or an RFP.
Pharma spans small-molecule drugs, formulations, prodrugs, and biologics—often overlapping with biotech. To keep comparisons fair and apples-to-apples, we anchor this view to CPC subclasses that most directly capture drug substances and preparations. We emphasize A61K (medicinal preparations) and core small-molecule classes C07D/C07H, with C12N included only when claims clearly reflect biotech-derived drug products (e.g., proteins, cell therapies).
For our purposes, device-only claims (delivery hardware) live in Life Sciences unless the center of gravity is the drug formulation. Platform software or analytics claims sit in CS/IT unless they are drug-substance focused. For multi-industry filings, we classify by the primary CPC and standardized rules documented in the methodology.
A rotating spotlight on top practices from our list
Didn't make the list?
You have the talent. You just need the industry's best data to guide your strategy. Book a session with an expert from Juristat to become a Top Patent Firm.
.png "Pharmaceuticals - Dark Background (2)")
.png "Pharmaceuticals industry")
